HUANG Haojie
Department of Urology & Institute of Urologic Science and Technology
Prof. HUANG has over 15 years of experience in cancer research, focusing on genetic alteration, transcription and epigenetic reprogramming, cell lineage plasticity, and resistance to cancer therapies including immunotherapy. He is particularly interested in investigating the roles of clinically relevant factors in cancer, which include transcription factors (AR, FOXO1 and ERG), chromatin modifiers (EZH2 and LSD1), and tumor suppressors (SPOP, PTEN, RB and TP53). The ultimate goal of his research is to understand the molecular mechanisms of therapy resistance in cancer and to define new targets for treatment of this lethal disease. Professor Huang have been working at Mayo Clinic for 22 years and jointed FAHZU last year. His research program has been continuously funded by multiple NIH R01 grants, DOD Idea Development Awards, and Prostate Cancer Foundation Challenge Award in the United States since 2004. He has published over 170 papers and book chapters, some of which are in high profile journals such as Science, Nature Medicine, Cancer Cell, Nature Cell Biology, Science Advances, Nature Communications, European Urology, Molecular Cell, PNAS, EMBO J, etc. He was the President of the Society of Basic Urologic Research (SBUR) and is currently serving on the Editorial Board of several journals including Cancer Research, Cancer Research Communications and others.